Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 5:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 569 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Clear all
Completed Phase 1Phase 2 Interventional

Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma

NCT00003616
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
irinotecan hydrochloride
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 11, 2026, 5:21 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma

NCT00949325
View directory record Official record
Conditions
Sarcoma
Interventions
temsirolimus plus liposomal doxorubicin
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
1 Year and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2019 · Synced Oct 11, 2026, 5:21 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.

NCT01732640
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Afatinib, Paclitaxel, Carboplatin, Cisplatin, Intensity Modulated Radiation Therapy
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 11, 2026, 5:21 AM EDT
Terminated Phase 2 Interventional Results available

Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer

NCT02516670
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Ascorbic Acid, Docetaxel, Laboratory Biomarker Analysis, Pharmacological Study, Placebo, Quality-of-Life Assessment
Dietary Supplement · Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Annapolis, Maryland • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 11, 2026, 5:21 AM EDT
Recruiting Phase 2 Interventional

Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

NCT06617923
View directory record Official record
Conditions
Ovary Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer
Interventions
Senaparib, Temozolomide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 11, 2026, 5:21 AM EDT
Terminated Phase 2 Interventional

Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

NCT00003561
View directory record Official record
Conditions
Leukemia
Interventions
recombinant interferon alfa, sargramostim
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Oct 11, 2026, 5:21 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer

NCT04331717
View directory record Official record
Conditions
Prostate Adenocarcinoma, Obesity, Morbid
Interventions
Bead Block 300-500 um, Weight Management, Lupron
Device · Behavioral · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 11, 2026, 5:21 AM EDT
Completed Phase 2 Interventional Results available

Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma

NCT01045460
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Activated marrow infiltrating lymphocytes, Allogeneic Myeloma Vaccine, Cyclophosphamide, Filgrastim, Leukapheresis, Melphalan, Autologous stem cell transplant
Biological · Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 9, 2021 · Synced Oct 11, 2026, 5:21 AM EDT
Terminated Phase 1 Interventional

FBnTP Imaging of Breast Cancer

NCT02204462
View directory record Official record
Conditions
Breast Cancer
Interventions
FBnTP
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
26 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 11, 2026, 5:21 AM EDT
Withdrawn No phase listed Observational

Head and Neck Cancer Treatment Related Dysphagia

NCT02657850
View directory record Official record
Conditions
Head and Neck Cancer, Dysphagia
Interventions
non- head and neck self reporting, head neck self reporting, provider reporting
Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Scottsdale, Arizona • Aurora, Colorado • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Oct 11, 2026, 5:21 AM EDT
Completed Phase 2 Interventional

Cyclophosphamide Plus Topotecan in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia

NCT00003340
View directory record Official record
Conditions
Leukemia
Interventions
cyclophosphamide, topotecan hydrochloride
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 2, 2014 · Synced Oct 11, 2026, 5:21 AM EDT
Completed Not applicable Interventional

Observation of Perioperative Outcomes of Robotic Pancreaticoduodenectomy

NCT04171440
View directory record Official record
Conditions
Pancreaticoduodenectomy
Interventions
robotic pancreaticoduodenectomy
Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Baltimore, Maryland • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 11, 2026, 5:21 AM EDT
Recruiting Phase 2 Interventional

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

NCT07281768
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Oxaliplatin, Capecitabine, Cemiplimab, Fianlimab, REGN7075
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 11, 2026, 5:21 AM EDT
Completed Phase 2 Interventional Results available

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

NCT05014776
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Tadalafil, Pembrolizumab, Ipilimumab, CRS-207
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 11, 2026, 5:21 AM EDT
Completed Phase 1 Interventional

SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)

NCT01966289
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
CY, GVAX, SGI-110
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 11, 2026, 5:21 AM EDT
Terminated Phase 2 Interventional Results available

MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple Myeloma

NCT03218163
View directory record Official record
Conditions
Multiple Myeloma
Interventions
MEDI-551 Maintenance
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Oct 11, 2026, 5:21 AM EDT
Completed Phase 2 Interventional

Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer

NCT00244959
View directory record Official record
Conditions
Breast Cancer
Interventions
anastrozole, adjuvant therapy
Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 19, 2013 · Synced Oct 11, 2026, 5:21 AM EDT
Completed Phase 1Phase 2 Interventional

CCI-779 in Treating Patients With Malignant Glioma

NCT00022724
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
temsirolimus
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Bethesda, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 11, 2026, 5:21 AM EDT
Completed Phase 1 Interventional

Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide

NCT01729260
View directory record Official record
Conditions
Newly Diagnosed High-Grade Glioma
Interventions
Mebendazole
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Oct 11, 2026, 5:21 AM EDT
Completed Not applicable Interventional Results available

Combined Technology Enhanced Home Exercise Program and Other Non-pharmacological Intervention for Cancer Survivors

NCT03576274
View directory record Official record
Conditions
Cancer-related Problem/Condition, Exercise, Acupressure
Interventions
Technology Enhanced Home Exercise (TEHE), Auricular Point Acupressure (APA), Mindfulness body scan (MBI)
Behavioral
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
21 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 11, 2026, 5:21 AM EDT
Active, not recruiting Phase 1 Interventional

Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors

NCT03875287
View directory record Official record
Conditions
Solid Tumor
Interventions
Decitabine, Cedazuridine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 11, 2026, 5:21 AM EDT
Active, not recruiting Phase 2 Interventional

Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca

NCT04848116
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Nivolumab, HuMax-IL8
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 11, 2026, 5:21 AM EDT
Recruiting Not applicable Interventional

Exercise in Prostate Cancer

NCT06165302
View directory record Official record
Conditions
Prostate Cancer Metastatic, Prostate Cancer
Interventions
Exercise Intervention
Behavioral
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 11, 2026, 5:21 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Transplantation of Umbilical Cord Blood Following Chemotherapy for Blood Cancers

NCT00539656
View directory record Official record
Conditions
Acute Myeloid Leukemia, Leukemia, Lymphoblastic, Acute, Leukemia, Bilineage, Acute, Leukemia, Myeloid, Chronic
Interventions
Ex vivo expansion of cord blood
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
6 Months to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Oct 11, 2026, 5:21 AM EDT